Reflections from the OARSI 2022 clinical trials symposium: The pain of OA —Deconstruction of pain and patient-reported outcome measures for the benefit of patients and clinical trial design

Osteoarthritis (OA) drug development is hampered by a number of challenges. One of the main challenges is the apparent discordance between pain and structure, which has had a significant impact on drug development programs and has led to hesitance among stakeholders. Since 2017, the Clinical Trials Symposium (CTS) has been hosted under the Osteoarthritis Research Society International (OARSI) leadership. OARSI and the CTS steering committee yearly invite and encourage discussions on selected special subject matter between regulators, drug developers, clinicians, clinical researchers, biomarker specialists, and basic scientists to progress drug development in the OA field.

Source: Osteoarthritis and Cartilage - June 26, 2023 Category: Rheumatology Authors: MA Karsdal, J Tambiah, D Felson, C Ladel, NP Nikolov, D Hodgins, AR Bihlet, T Neogi, C. Baatenburg de Jong, AC Bay-Jensen, R Baron, A Laslop, A Mobasheri, VB Kraus Tags: Review Source Type: research